- What is Neurim Pharmaceuticals' primary focus?
- Neurim Pharmaceuticals is a drug discovery and development company focused on creating drugs for brain restoration and ongoing support, addressing insomnia, central nervous system problems, and neurodegenerative diseases.
- What is Neurim Pharmaceuticals' first approved drug?
- Neurim Pharmaceuticals' first approved drug is Circadin, a timed-release melatonin for insomnia, which is commercially available in Europe, the AsiaPacific region, and the Middle East.
- Has Neurim Pharmaceuticals received any recent marketing authorization recommendations for its products?
- Yes, the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorization for Slenyto, a pediatric prolonged-release melatonin-coated tablet formulation for the treatment of children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome who suffer from insomnia.
- Where is Neurim Pharmaceuticals headquartered?
- Neurim Pharmaceuticals is headquartered in Tel Aviv-Yafo, Israel, with an additional office in Zug, Switzerland.
- When was Neurim Pharmaceuticals founded?
- Neurim Pharmaceuticals was founded in June 1991.
- Who is a co-founder of Neurim Pharmaceuticals?
- Nava Zisapel is a Co-Founder and CSO of Neurim Pharmaceuticals.
- What is the employee count for Neurim Pharmaceuticals?
- Neurim Pharmaceuticals has 11-50 employees.
- What is Neurim Pharmaceuticals' primary sector?
- Neurim Pharmaceuticals' primary sector is Health Tech & Life Sciences.
